TFF Pharmaceuticals Inc

TFFP

$6.19

Closing

▼-6.07%

1D

▼-11.82%

YTD

Market cap

$15.22M

52 week high

$20.50

52 week low

$4.55

Volume

13,914

Check if the stock is halal

Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.

We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.

Get started from just $3.99/month

Market cap

$15.22M

Analysts' Rating

BUY

Price Target (Mean)

8

Total Analysts

2

P/E

Operating Margin

-1883.03%

Beta

1.27

Revenue Growth (Annual)

462.39%

52 week high

$20.50

52 week low

$4.55

Div. Yield

%

EPS Annual Growth

-35.71

Note on Purification and Zakat

  • Purification and Zakat (for long-term investing) calculations are in USD per share and based on AAOIFI methodology. AAOIFI requires purification every financial period (e.g. quarterly). 
  • If you follow S&P Shariah’s Dividend-only purification, then remove the impure income % from the dividends you receive. No purification required for non-dividend paying stocks, according to S&P Shariah.
  • For Zakat, if you did not invest in a company from a long term perspective, then consider the shares as trading goods and give 2.5% of the total value if a year has passed on them. 

Company Profile

TFF Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing drug products based on its patented Thin Film Freezing (TFF), technology platform. The TFF platform is designed to improve the solubility of poorly water-soluble drugs and is particularly suited to generate dry powder particles with properties targeted for inhalation delivery, especially to the deep lung, an area of extreme interest in respiratory medicine. The Company has two product candidates in clinical trials, which include TFF Voriconazole Inhalation Powder (TFF VORI) and TFF Tacrolimus Inhalation Powder (TFF TAC). TFF VORI is a next-generation, direct-to-lung, inhaled dry powder formulation of voriconazole in development for the treatment and prevention of invasive pulmonary aspergillosis (IPA), a severe fungal pulmonary disease. TFF TAC is an inhaled dry powder version of tacrolimus, an immunosuppressive drug used in transplant medicine.